ALL-071: A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Recommended Citation
Khan SS, Mori S, Jeyakumar D, et al. ALL-071: A Phase 4 Study to Evaluate Outpatient Blinatumomab in Patients with Minimal/Measurable Residual Disease (MRD) Positivity (+) of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). Clinical lymphoma, myeloma and leukemia. 2021;21:S266-S266.
Presentation Notes
Poster presented at: SOHO 2021; September 8-11, 2021; Virtual.
Document Type
Abstract
Affiliations
Advocate Lutheran General Hospital